Deliver Plus offers both UK and international express courier delivery. Our healthcare division was established to meet the specialist needs of the biotechnology, pharmaceutical and clinical research industries. Our team of experts understands your specialist requirements and can help ensure your clinical trial operates to plan every time. Our managed service offers you a tailored, pro-active service with a dedicated, named account manager assigned to your account. Through our global network of partners Deliver Plus provides express delivery to over 220 countries worldwide and serves many major destinations. We can support cold storage and distribution of life science materials.
Deloitte is the UK's fastest growing professional services firm in locations across the UK, with over 10,000 staff worldwide. Deloitte offers integrated services including audit, tax, consulting and corporate finance. Our approach combines insight and innovation from multiple disciplines with business and industry knowledge to help our clients excel anywhere in the world. We deliver outstanding impact on the reputation and success of our clients, in the UK and globally. Our industry specialists from across Deloitte provide an extensive depth of knowledge on the range of current issues experienced by the pharmaceuticals, biotechnology, medical devices and private healthcare industries.
DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens.
We've developed a novel technology to significantly increase the protective ability of vaccines, and develop them on a dramatically accelerated timeline. The system is currently in use to develop vaccines against Ebola, flu, and other deadly pathogens.
Discovery Park in Sandwich, Kent is a global leader for science and enterprise with world class laboratories and exceptional office space. The site has a track record for drug discovery stretching back to the 1950’s and continues to lead the way in R&D from the search for new antibiotics to pioneering research across the life sciences; from developing new therapeutics and diagnostics to unlocking the full potential of immunotherapy and immuno-oncology.
As well as industry-leading laboratories for R&D and bespoke office space, we can help businesses searching for the right location to manufacture their products or store with our bespoke warehousing options – all in a stunning, collaborative and inspirational campus environment. Thanks to Enterprise Zone status, businesses can also access a range of benefits – from free Wi-fi and funding advice to streamlined planning.
Whether you’re looking for start-up space to launch your business venture or a global headquarters for your company, we have all you need at Discovery Park to take your business to the next level.
Discuva is a Cambridge, UK-based drug discovery company producing new antibiotics to meet the critical unmet medical need in the clinic. The company has proprietary technologies that allow the rapid identification and development of targeted next generation antibiotics against emerging and drug-resistant pathogens. Discuva currently has several specific antimicrobial programmes mainly focused on Gram-negative bacteria that cause major hospital and community-based infections. The small molecule drugs produced by Discuva are being developed to have two major advantages over conventional antibiotics; no development of cross resistance and fewer side effects giving safer, more effective treatments with a longer market life.
DIVERSA Technologies (DIVERSA) is a biotechnology company that specializes in the development of novel drug delivery systems based on lipid nanoemulsions (LNEs) for small drugs and complex macromolecules (peptides, proteins, and oligonucleotides), increasing their stability and boosting their therapeutic activity.
DIVERSA offers its technology in the form of ready-to-go kits for the entire research community: universities, research centers, Contract Research Organizations, biotech and pharma companies. It offers co-development contracts to biotech and pharma companies with the possibility of sublicensing the technology for specific indications and, it develops its own R&D projects.
Strategic Expertise, Operational Excellence.. . A forward thinking regulatory affairs consultancy with more than 250 cumulative years regulatory experience spanning many therapeutic specialities. We offer the full range of regulatory affairs services from strategic advice in early drug development, to compilation and management of regulatory submissions, and for over 10 years we have helped companies of all sizes and backgrounds maximise the commercial value of their product. We also understand the importance of a clear regulatory strategy and pathway to market which can maximise the value of an asset when negotiating out-licensing agreements, and our proactive collaborative interactions with Regulatory Authorities can improve chances of approval of a product in the optimal time.
Domainex offers services including highly experienced computational and medicinal chemistry and a unique patented technology called CDH. . . Our unique LeadBuilder technology for finding in a highly cost effective manner robust developable hits. LeadBuilder has been used many times for clients in the academic or biotech areas with great effect. Our medicinal chemistry expertise is based upon a team of highly experienced medicinal chemists based in Cambridge with a history of working for leading European Pharma and Biotech. We specialise in tackling a broad range difficult targets for drug discovery, including peptidomimetics.. . Combinatorial Domain Hunting or CDH is a unique patented technology conceived by Prof Laurence Pearl’s team of leading structural biologists and is specifically aimed at expressing protein targets for drug discovery that can not be expressed by other approaches. CDH has been applied to targets from many leading Pharma.. . Domainex also has its own drug discovery pipeline. Domainex’s lead project is IKK epsilon which is in lead optimisation for breast cancer. Domainex also has a pipeline of lysine methyl transferases (KMTs) all targeted at cancer. Our unique CDH technology has been applied to a number of KMTs with the aim of producing unique x-ray structures and assays.